Skip to main content

Advertisement

Table 4 Results of ROC analysis and PPV, NPV, and accuracy of predicting PFS > 4 months versus PFS ≤ 4 months

From: 18F-FDG and 11C-4DST PET/CT for evaluating response to platinum-based doublet chemotherapy in advanced non-small cell lung cancer: a prospective study

Modality Parameter or interim assessments AUC PPV NPV Accuracy
CT RECIST 1.1 0.56 60.0 66.7 61.1
FDG Highest SUVmax 0.51 60.0 57.1 59.1
Sum of SUVmax 0.52 41.7 30.0 36.4
MTV 0.65 77.8 61.5 68.2
TLG 0.62 66.7 53.8 59.1
%Δhighest SUVmax 0.61 66.7 55.6 61.1
%Δsum of SUVmax 0.53 61.5 60.0 61.1
%ΔMTV 0.61 66.7 55.6 61.1
%ΔTLG 0.64 66.7 66.7 66.7
EORTC 0.60 70.0 55.6 66.7
PERCIST 0.59 61.5 60.0 72.2
4DST Highest SUVmax 0.70 80.0 66.7 72.7
Sum of SUVmax 0.51 40.0 71.2 40.9
MTV 0.73 80.0 66.7 72.7
TLP 0.72 72.7 63.6 68.2
%Δhighest SUVmax 0.64 58.3 57.1 57.9
%Δsum of SUVmax 0.65 70.0 66.7 68.4
%ΔMTV 0.59 60.0 55.6 57.9
%ΔTLP 0.59 58.3 57.1 57.9
  1. MTV metabolic tumor volume, TLG total lesion glycolysis, SUL standardized uptake value normalized by lean body mass, TLP total lesion proliferation